Group 1: Savara Inc. (SVRA) - A shareholder class action lawsuit has been filed against Savara Inc. alleging that the company made materially false and/or misleading statements regarding its biologics license application for MOLBREEVI between March 7, 2024, and May 23, 2025 [1] - Investors who purchased Savara shares during this period and suffered significant losses are encouraged to discuss their legal rights [1] Group 2: Fly-E Group, Inc. (FLYE) - A shareholder class action lawsuit has been filed against Fly-E Group, Inc. alleging that the company made materially false and/or misleading statements regarding its lithium battery, supply chain changes, regulatory environment, and demand fluctuations for E-Bikes and E-Scooters between July 15, 2025, and August 14, 2025 [2] - Investors who purchased Fly-E shares during this period and suffered significant losses are encouraged to discuss their legal rights [2] Group 3: Lantheus Holdings, Inc. (LNTH) - A shareholder class action lawsuit has been filed against Lantheus Holdings, Inc. alleging that the company created a false impression regarding its projected revenue outlook and anticipated growth while minimizing risks from competition, pricing dynamics, seasonality, and macroeconomic fluctuations between February 26, 2025, and August 5, 2025 [3] - Investors who purchased Lantheus shares during this period and suffered significant losses are encouraged to discuss their legal rights [3] Group 4: Holzer & Holzer, LLC - Holzer & Holzer, LLC is a top-rated securities litigation law firm that represents shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation [4] - The firm has recovered hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct since its founding in 2000 [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 7, 2025 [2] - The lawsuit claims that Savara's defendants made false or misleading statements regarding the approval process of the MOLBREEVI Biologics License Application (BLA) [4] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3] - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking No. 1 for settlements in 2017 [3] Group 3: Case Specifics - The lawsuit alleges that the defendants failed to disclose critical information about the MOLBREEVI BLA, which affected the likelihood of FDA approval and the company's capital needs [4] - The claims suggest that the public statements made by the defendants were materially false and misleading, leading to investor damages when the true information became public [4]

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares of common stock, including 4,642,857 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at $4.20 per share. In addition, in lieu of shares of common stock, Savara sold to cer. ...

Core Insights - Savara Inc. (NASDAQ:SVRA) is identified as a promising stock under $5 with significant upside potential, with Citizens JMP raising its price target from $8 to $11 while maintaining an Outperform rating [1] - A survey conducted by Citizens JMP indicates strong demand for Molbreevi, with 60% of pulmonologists expressing willingness to use it, suggesting potential for blockbuster sales as Savara plans to resubmit its application in December [2] - LifeSci Capital initiated coverage on Savara with a Buy rating, highlighting the promising outlook for Molbreevi, which targets autoimmune pulmonary alveolar proteinosis (aPAP), a rare disease lacking approved treatments in the EU and US [3][5] - Expert feedback suggests that Molbreevi's unique formulation as a large inhaled biologic may help it achieve blockbuster status in the US market, providing a competitive edge against biosimilars [4] Company Overview - Savara Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapies for serious or life-threatening rare respiratory diseases, including molgramostim, an inhaled formulation of recombinant human GM-CSF for treating aPAP [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the November 7, 2025 deadline [2] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [5] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3] - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly in securities class action settlements since 2013 [3] Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [4] - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital, and that public statements made by the defendants were materially false and misleading [4]

Core Points - Rosen Law Firm is reminding investors about a class action lawsuit filed on behalf of Savara Inc. (NASDAQ: SVRA) shareholders for the period between March 7, 2024, and May 23, 2025 [1][4] - The lawsuit alleges that Savara misled investors regarding its business operations, particularly concerning the Biologics License Application (BLA) for MOLBREEVI, a treatment for a rare lung disease [2][3] Allegations - The lawsuit claims that Savara's BLA for MOLBREEVI lacked sufficient information on its chemistry, manufacturing, and controls, making FDA approval unlikely in its current form [3] - It is alleged that Savara would not complete the BLA submission within the previously represented timeframe, increasing the likelihood of needing additional capital [3] - The public statements made by Savara were claimed to be materially false and misleading, resulting in investor damages when the true details emerged [3] Legal Proceedings - Investors interested in serving as lead plaintiffs must file motions with the court by November 7, 2025 [4] - Participation in the case is not required to be eligible for recovery, allowing investors to remain absent class members if they choose [4] Rosen Law Firm Overview - Rosen Law Firm specializes in shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6]

Core Viewpoint - Savara Inc. has announced the pricing of a public offering of common stock and pre-funded warrants, indicating a strategic move to raise capital for its operations focused on rare respiratory diseases [1] Group 1: Offering Details - The company is offering 23,809,524 shares of its common stock at a price of $4.20 per share [1] - Additionally, the offering includes pre-funded warrants to purchase 7,142,857 shares of common stock at a price of $4.199 per warrant [1] - The pricing is set before deducting underwriting discounts and commissions, highlighting the financial structure of the offering [1]

Group 1 - Savara Inc. is presenting data on its investigational treatment, molgramostim, which is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) [1][3] - The presentation highlights positive results from the Phase 3 IMPALA-2 trial, demonstrating molgramostim's ability to enhance lung diffusing capacity [2] - Savara is a clinical-stage biopharmaceutical company focused on therapies for rare respiratory diseases, with molgramostim being its lead product candidate [3]

Core Viewpoint - A class action securities fraud lawsuit has been filed against Savara Inc. by Pomerantz LLP, correcting a previous statement regarding the filing firm [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for shareholders affected by alleged securities fraud occurring between March 4, 2024, and May 23, 2025 [2]. - The complaint alleges that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for the treatment of pulmonary alveolar proteinosis, indicating insufficient information about its chemistry, manufacturing, and controls [3]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay the submission timeline previously communicated to investors [3]. Group 2: Implications for Investors - The delay in regulatory approval for MOLBREEVI increases the likelihood that Savara would need to raise additional capital, impacting shareholder value [3]. - Shareholders who suffered losses during the relevant timeframe are encouraged to seek recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP is highlighted as a nationally recognized securities litigation firm with a strong track record in securing recoveries for shareholders [5]. - The firm has been consistently ranked among the top securities litigation firms in the United States, emphasizing its expertise in complex securities cases [5].

Core Viewpoint - Savara Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between March 4, 2024, and May 23, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for the treatment of pulmonary alveolar proteinosis, indicating insufficient information about its chemistry, manufacturing, and controls [2] - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2] - The public statements made by the defendants were materially false and misleading throughout the relevant period [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]